5990-32-9Relevant articles and documents
Europium(III)-containing zinc oxide from Pechini method
Lima,Sigoli,Davolos,Jafelicci Jr.
, p. 280 - 284 (2002)
ZnO:Eu3+ (0.1 and 3 at%) with average particle size of 500 nm were prepared by the Pechini method. Photoluminescence spectroscopy evidences that there is no energy transfer between ZnO and Eu3+ ion. The emission spectrum at 77 K show
Phase transition of hollow-porous α-Fe2O3 microsphere based anodes for lithium ion batteries during high rate cycling
Hao, Shiji,Zhang, Bowei,Ball, Sarah,Wu, Junsheng,Srinivasan, Madhavi,Huang, Yizhong
, p. 16569 - 16575 (2016)
In the present paper, hollow-porous α-Fe2O3 microspheres are prepared via cation etching of zinc citrate microspheres and subsequent thermal treatment. The superior performance of the as-obtained α-Fe2O3 microspheres as an anode material for lithium ion batteries is evaluated. After 1000 cycles, the capacity still remains more than 1100 mA h g-1 at a current rate of 1 A g-1. Meanwhile, the crystal size induced phase transition of Fe2O3 microspheres (α → γ → β) is observed during cycling by the measurements of ex situ XRD and TEM, which is responsible for their abnormal performance fluctuation.
Electron Density Distribution in the Crystal of the Biocompatible Metal–Organic Framework
Ishchenko, A. A.,Nelyubina, Yu. V.,Pak, A. M.
, p. 16 - 25 (2022/03/17)
Abstract: The earlier described organic coordination polymer [Zn3(HCit)2(H2O)2]n (HCit is citric acid) (I) formed completely by the biocompatible components is synthesized under hydrothermal conditions. The selection of the hydrothermal synthesis conditions makes it possible to obtain the polymer as high-quality single crystals and perform a detailed analysis of the electron density distribution function recovered using the data of a high-resolution X-ray diffraction experiment. This study is the second example of such investigations for the biocompatible metal?organic framework.
MAGNESIUM CITRATE GLYCINATE CO-SALT
-
Paragraph 0072-0073, (2021/06/26)
A magnesium citrate glycinate co-salt has a formula of Mg2C8H9NO9 - X H2O and a suggested structure of Formula I. The magnesium citrate glycinate co-salt has an apparent density of 1740 kg/m3 and is compressible in a range of compression pressures from approximately 50 MPa to approximately 150 MPa. The magnesium citrate glycinate co-salt is formed by combining citric acid and glycine in a 1:1 molar ratio to form an aqueous reaction mixture and neutralizing the aqueous reaction mixture with a magnesium source having a magnesium:ligand ratio of 1:1.
MATERIALS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH PATHOGENIC BIOFILM
-
, (2019/04/30)
The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more prebiotic or probiotic organisms. In a further embodiment, the prebiotics are delivered via a wax disposed on a dental floss.
A zinc citrate trihydrate synthetic method
-
Paragraph 0027; 0028; 0029; 0030, (2016/11/21)
The invention relates to a method for synthesizing zinc citrate trihydrate. The method comprises the following steps: adding citric acid and deionized water into a reaction kettle, and stirring and heating to the temperature of 55-65 DEG C; adding a zinc compound, adding a catalyst and aids after the zinc compound is completely added, stirring, heating, and reacting; centrifuging and filtering after the reaction is ended, sequentially washing and performing absolute ethyl alcohol washing on the obtained solids; and finally, fully performing vacuum drying, thereby obtaining the zinc citrate trihydrate. According to the method, a complex reaction system with specific catalyst and aids is adopted, rapid and high-yield preparation of the target product is realized by virtue of dual effects of the micro-hole reaction environment and assistant catalysis, and the method has very obvious technical effects and achieves wide industrial application prospects and market potentials.
PREPARATION OF ZINC CITRATE AND OF ZINC CITRATE-CONTAINING ORAL CARE COMPOSITIONS
-
Paragraph 0058, (2016/06/06)
A method of preparing a zinc citrate-containing oral care composition, the method comprising: (a) adding zinc oxide to a solution of citric acid in a solvent to form a suspension; (b) agitating the suspension until a clear solution is obtained; and (c) adding an additional oral care ingredient to the solution obtained in (b). Also, a method of preparing a zinc citrate-containing oral care composition, the method comprising: (a) adding citric acid to a suspension of zinc oxide in a solvent; (b) agitating the suspension until a clear solution is obtained; and (c) adding an additional oral care ingredient to the solution obtained in (b). In both methods, steps (a) and (b) are carried out at a temperature of from 10°C to 50°C and the molar ratio of zinc oxide to citric acid in step (a) is about 3:2.
